

*OCP*

## INFORMATION REPORT INFORMATION REPORT

## CENTRAL INTELLIGENCE AGENCY

This material contains information affecting the National Defense of the United States within the meaning of the Espionage Laws, Title 18, U.S.C. Secs. 793 and 794, the transmission or revelation of which in any manner to an unauthorized person is prohibited by law.

25X1

S-E-C-R-E-T

OUNTRY	East Germany	REPORT	
JBJECT	Description of Various Human and Animal Pharmaceuticals	DATE DISTR.	29 January 1957
ATE OF INFO.		NO. PAGES	1
LACE & ATE ACQ.		REQUIREMENT NO.	RD
		REFERENCES	

*(11)*

*(1)*

25X1

SOURCE EVALUATIONS ARE DEFINITIVE. APPRAISAL OF CONTENT IS TENTATIVE.

25X1

reports (in English) describing various human and animal pharmaceuticals, presumably manufactured by the East German factory named below

25X1

Annex A -- description of "Oestrastilben-D," a 4,4-dimethoxy-1,2-diethylstilben, "for Prostatic Diseases and Other Indications in the Deposit Therapy of Follicle Stimulating Hormones," apparently manufactured by VEB Pharmazeutisches Werk Berlin-Johannisthal. (9 pages in English)

*LY*

Annex B -- description of vitamin K "Pharma," a 2-methyl-1,4-naphthochinon-sodium bisulphite, apparently manufactured by VEB Pharmazeutisches Werk Berlin-Johannisthal. (6 pages in English)

Annex C -- description of Olypon AFE, an "auxiliary colouring matter for sulphur dyeing" of textiles, apparently manufactured by VEB Chemische Fabrik Gruenau. (4 pages in English)

Annex D -- description of various pharmaceuticals listed in the "Veterinary Drug Catalogue 1956," apparently these preparations are being manufactured by VEB Chemische Fabrik Falkensee. (6 pages in English)

Annex E -- another listing and description of pharmaceuticals from the "Veterinary Drug Catalogue 1956," stating that these preparations are being manufactured as of 1 January 1956 by VEB Chemische Fabrik Falkensee; the report also contains a brief description of conditions for sale and delivery. (6 pages in English)

25X1

*101*

S-E-C-R-E-T

25X1

ATE	X ARMY	X NAVY	X AIR	X FBI	AEC				
-----	--------	--------	-------	-------	-----	--	--	--	--

Note: Washington distribution indicated by "X"; Field distribution by "#".

INFORMATION REPORT INFORMATION REPORT

Annex A

卷之三

Sanitized Copy Approved for Release 2010/02/16 : CIA-RDP80T00246A032301010001-0

O N T R A S T I L D R A M P  
(Deposit)

General:

13832

In course of the systematic researches concerning the endocrine processes within the organism the hormones have gained, especially during the latest years past, more and more importance for the therapy in the line of various complaints. At the same time, however, also the more particular knowledge of the connections has resulted in refined methods of the hormone therapy of improved accommodation to given physiological conditions.

The natural work of the gland with its continuous secretion of hormones is faced, in case of endocrine insufficiency, a relatively but short-time and not continuous influence on the endocrine system if simple hormone preparations are given orally or parenterally. Such medication entails, especially upon higher dosages of simple hormone preparations, a sudden and excessive offer of hormones which cannot entirely utilized at once and are partially eliminated again according to the flow over principle. Disregarding the variations in the hormone level caused in this way and deteriorating the therapy conditions, in this connection just the extragenital influences of female sex hormones frequently take disturbing effect. In the event of insignificant biological and pathological deteriorations of hormonal action such influences can be obviated to largest extent by well adapted dosing of the drug; this is not true, however, in case of far-reaching endocrine insufficiency and disturbance of the ovarian function as well as in the event of diseases responding only to prolonged medication of highly dosed follicle stimulating hormones.

Practical medicine, therefore, is asking for the treatment of such diseases, for follicle stimulating hormone drugs securing, according to their deposit-like effect, a balanced hormone level which is maintained for prolonged time, and that without regard to the facilitations offered by the reduced frequency of application of such preparations both to the doctor and to the patient.

In contradistinction to the esterification of oestrogens matters making them staying in the organism, according to their chemical structure, for a more or less prolonged time, and to the utilization of "physical deposits" in shape of implantations and crystal suspensions, the "Oestrastilben D" effects an etherification of a synthetic oestrogen to a so-called "conversion deposit". This term denotes a medical matter chemical structure of which makes it ineffective at the time of application, and which does not take effect within the organism until upon conversion into a medicament attaining the end the therapy is aiming at, and that by splitting off or other biochemical processes. The forced protracting effect is based on the duration of the conversion process.

Symbol:

"OESTRASTILBEN D" is a 4\*4-dimethoxy-1\*2-diethylstilben. One ampoule of 2 ccms contains 12 milligrams of the bio-catalyst dissolved in clean sodium tauri.

It is believed that the injection of the dimethoxydiethyl-stilben effects a so-called conversion deposit; that means, according to Rizzo (1), that the effect of such deposit is to be released secondarily by a slowly proceeding chemical reaction within the body. According to this such dimethyl ether is biologically inactive. Not earlier than within the organism the oestrogen-effective dioxydiethylstilben is set free by gradual splitting-off of the two methyl groups, and, streaming slowly into the blood-ducks, it takes long lasting oestrogenous effect. The splitting-off process of the methyl groups is extended, according to the doses applied, to a couple of weeks, thus resulting in an extremely small elimination of the dimethyl ether.

Pharmacological:

The testing of the dimethoxydiethylstilben according to known international units does not permit any comparative utilisation against other simple synthetic oestrogens, due to the characteristic mode of effect of this preparation. Small doses of "OESTRASTILBEN D" are able to release a not very impressive oestrus at a gelded female rat, it is true, but such effect could have been attained also by fractions of such doses of simple follicle stimulating hormones. The deposit

- 4 -

effect entailing a rutting season lasting for weeks does not appear until a higher - and varying - dosing threshold is exceeded. By this behaviour of the preparation the splitting-off process proceeding in small partial quantities within a prolonged time may be considered proved. Apart from this animal experiments resulted in completely coincident effects when comparing "OESTRASTILBEN D" with other preparations of similar structure.

Local injuries, stimulating effects, or toxic phenomena were not observed when using "OESTRASTILBEN D" for animal experiments. The pharmacological test of the preparation has been executed in the Gynaecological Institute of the University at Leipzig under the direction of Prof. Dr. Haenschild. The production of "OESTRASTILBEN D" is continuously supervised and controlled by the Institute for Experimental Endocrinology to the Humboldt-University at Berlin under the direction of Prof. Dr. Hohlweg.

#### Informing Hints:

"OESTRASTILBEN D" is applied by intramuscular injections. The effect appears in general after 4 or 5 days; with bad reactivity, however, it may be belated up to about 10 days. As to the duration of effect several authors agree on a time of 6 weeks in average whereas both shorter and longer effects have been observed.

Except the sexual by-effects phenomena of incompatibility have not been recognized in any case of application.

The clinical test of the preparation has been carried on: in the line of gynaecology by the

Gynaecological Infirmary of the University at Leipzig,  
Director: Prof. Dr. Schröder,

Gynaecological Infirmary of the University at Berlin,  
Director: Prof. Dr. Kratz;

In the line of internal medicine by the

II<sup>nd</sup> Medical Infirmary of the University at Halle,  
Director: Prof. Dr. Ratschow;

In the line of surgery and urology by the

Surgical Infirmary of the University at Rostock,  
Director: Prof. Dr. Keritsky.

- 5 -

Indications and Dosage:

25X1

Menopause as a Syndrome of the Outfall Symptoms

Whereas in former times without any objection oestrogens were frequently applied for treating the outfall symptoms in menopause recently has been pointed out more than once that the climacteric period should be considered as a biological process course of which should be controlled by carefully dosed medications of hormones only in the event of severe pathologic deficiency.

Inject one ampoule of 12 milligrams "OESTRADIOLBEN D", and repeat this medication, according to the gravity of the symptoms, in intervals of not less than 8 days. For younger patients with artificially induced menopause one application of 24 milligrams should be preferred. Higher dosages should be desisted from, due to the existent danger of suspended bleeding.

Upon the application of "OESTRADIOLBEN D" characteristic outfall symptoms such as flushes and sweats do not appear any longer, or are lessened to a minimum (2). Also the syndrome of other troubles occurring in this connection is influenced advantageously. Especially impressively the favourable effect of "OESTRADIOLBEN D" has turned out after severe genital operations of younger women.

Amenorrhoea:

According to the histologic finding based on the down-stroke curettage in hormonally conditioned secondary amenorrhoea 24 to 36 milligrams of the preparation are applied. The repeated down-stroke curettage carried out after 3 weeks will prove in most cases a drastically proliferating mucosa (2). In trifling cases frequently already the sole application of "OESTRADIOLBEN D" in intervals of four weeks will result in a normal cycle. In tenacious cases with mostly atrophic functionalis we recommend to repeat the therapy which, if necessary, should be combined with an application of corpus luteum hormon according to the monthly cycle.

Hormonotherapy for Malign Growth:

Beside their use for treatments with palliative objective the sex hormones - and in this connection particularly the female sex hormones - have been successfully applied up to now

only in therapies for cancerous diseases within the sexual regions, and that for the inoperable cancer of the breast, the incurable genital cancer, and the prostatic cancer. According to recent opinions the body-own homosexual hormones (the oestradiol for mammary and genital carcinoma, and the testosterone for prostatic carcinoma) as well as gonadotropic hormones or, furthermore, other biocatalysts not yet known in particular and produced in the anterior lobe of the pituitary gland are deemed to encourage the canceration, too. The hormon therapy in acute cancerous diseases, therefore, is based in principle on a ligation of the secretion of pituitary hormones and, in this way, of the production of sex hormones in the reacting organ by suppression or immobilization of the pituitary gland by means of high doses of sex hormones.

As to the dosage of oestrogens in cancerous therapy recent animal-experimental examinations executed by Hohlweg and Schmauss (3) have resulted in changed points of view showing that, together with reduced hormone doses, the suppression of the pituitary gland is adequately released, and that even with constant dosage a certain habit-forming effect on the pituitary gland is achieved. The examinators therefore recommend to start the therapy with a dose sufficient for suppressing the pituitary gland, and to increase it, whenever possible, in course of the treatment in order to prevent any deterioration by an increased activity of the pituitary gland resulting from the lessening hormon level.

a) The Prostatic Carcinoma:

Whereas upon general opinion deposit-effective follicle stimulating hormones are considered as the agent of selection for the therapy in prostatic carcinoma the experiences concerning the methodics of dosing are still prejudged in quite different manner. But there is an unanimous demand for a relatively high deposit to be set in the very beginning of the therapy - and that about 6 ccms = 36 milligrams of "OESTRA-STILBEN D". The medication of this dose should be repeated in intervals of 10 days.

Now and then a decreasing responsiveness to a hormon preparation can be observed. In such cases we recommend to continue the treatment with oestraside preparations.

Under the effect of "OESTRASTILBEN D" a soon decrease of

metastatic pains and the inhibition of micturition as well as an acceleration of general condition can be observed. The follicle stimulating human therapy must not be stopped in any case.

#### b) Inoperable Cancer of the Breast:

The treatment of the inoperable cancer of the breast with homogenital hormones represents, according to Schmied (5), a valuable enrichment of the hitherto known kinds of therapy. In general a favourable influence effected by follicle stimulating hormone can be expected only in cases of cancers of the breast developed during menopause. According to experiences collected the treatment with follicle stimulating hormone is the better the older the patients are, resp. the longer time has elapsed since the beginning of menopause.

The definitive treatment of the cancer of the breast with oestrogens should be used only for patients who are not less than 5 years beyond their climacteric period.

Upon clinical experiences the treatment of the inoperable cancer of the breast with oestrogens requires considerably higher doses than that of the prostatic carcinoma. The daily medication should comprise up to 30 milligrams of free oestrogens. As to "TESTOSTERONE" we recommend to apply twice a week 2 capsules of 15 milligrams in total. Also the treatment of the cancer of the breast with oestrogens must not be interrupted in any case.

#### Hypertrophy of the Prostate Gland:

Obviously there are not any relations between the hypertrophy of the prostate gland and prostatic carcinoma. Their coincidence is considered still to-day quite incidental and occurring by chance. It is considered ascertained to largest extent that androgenous hormones are acting only in sense of a tonisation of the muscular wall of the bladder not excluding, however, any carcinogenic effect. Oestrogens, on the contrary, are inhibiting the secretory activity of the prostate gland.

Griswold and Dulke (6) differentiate the symptoms of hypertrophy of the prostate gland in adenomatous prostatic nodes with predominant male sex-hormone; in such case, therefore, the therapy with oestrogens should be applied. A fibromatous node, on the contrary, results from prevailing female sex-hormones and requires a treatment with testosterone pre-

- 8 -

operations. According to extended histological examinations the adenomatous type of the disease includes 69 % of the examined cases whereas 23.5 % of them represented a mixed type so that the oestrogen therapy was nearly exclusively indicated. Tschop (7), however, reports on better successes achieved with testosterone preparations at patients in the nineties of age. The amelioration or healing is assessed on base of the dysuria, nocturia, and residual urine.

Also the adenoma of the bladder-neck has been favourably influenced by oestrogens.

According to present experiences the hypertrophy of the prostate gland required higher initial dosages than the prostatic carcinoma. We recommend to set an initial deposit of 60 milligrams, i.e. 5 ampoules per 2 ccms with 12 milligrams of Oestrastilben D each, and to apply once a week 12 milligrams for a period of 8 weeks. During the treatment regular determinations of serum phosphatase should be made. If in tenacious cases the finished treatment results in a negative finding we advise to stop the treatment with this therapy.

#### Disturbed Passage of Blood:

The properties of the follicle stimulating hormone encouraging the passage of blood are making the "OESTRASTILBEN D" suitable also to most extended applications for organic and functional disturbances of passage of the blood as well as for circulatory and metabolic disturbances caused by the climacteric process.

As to the dosage we recommend the injection of firstly 1 ampoule of 12 milligrams of "OESTRASTILBEN D". According to the effect on the disease repeated medications of equal doses in intervals of about 10 days are indicated.

To women of generative age, if possible, only one injection of 12 milligrams should be applied within one cycle, and that on the fourth day after the beginning of the menstruation.

Sexual phenomena (reaction of mammary glands and disturbances of generative capacity) appearing at male patients under the effect of "OESTRASTILBEN D" are improved again within a short time after the therapy has been finished.

- 9 -

- 2 -

Gastric and Duodenal Ulcer:

25X1

In spite of the recent but nevertheless still uncertain methods of ulcer therapy the simultaneous application of follicle stimulating hormones together with usual dietary precautions and practices are highly esteemed now as before. Whereas the achievement of objective healing successes is still discussed the palliative value of the application of follicle stimulating hormones is hardly contested. According to present experiences the application of deposit-effective oestrogens represents without any doubt an improvement of the hitherto known therapeutical possibilities.

Dosage:

Start with 2 times 2 ccms of "OESTRASILBEN D" within the first week with subsequently decreasing doses.

Packings for Sale:

Original packing: 2 ampoules of 2 ccms with 12 milligrams of bicocatalyst each.

Clinical packing: 12 ampoules of 2 ccms with 12 milligrams of bicocatalyst each.

Literature:

- (1) Eldem: I. a.m.med. Assoc. 140, 1214 (1949) 53, 263 (1947)
- (2) Lüter: Dtsch.Ges.Vesem 25, 784 (1952)
- (3) Schmaus: Arch.Geschwulstforsch. 3, 201 (1954)
- (4) Rosolock: Dtsch.med. schr. 23, 770 (1951)
- (5) Schmaus: Z.d.rztl.Ferbildung 7/8, 176 (1952)
- (6) Glegmann & Drüke: Vortrag auf der 29. Tagung der Deutschen Gesellschaft für Gynekologie in München, Oktober 1952
- (7) Tachot: J.Ur.France 59, 195 (1952)

ERB 15/11/743

- 1 -

7888 x 15

25X1

25X1

Vitamin K "Pharma"

(2-methyl-1,4-naphthochinon-sodium bisulphite)

Pps  
J

VVG PHARMAZEUTISCHES GMBH JOHANNISTHAL

BERLIN-JOHANNISTHAL - AM FLUGPLATZ 6

25X1

VITAMIN K "PHARMA"

(2-methyl-1·4-naphthochinon-sodium bisulphite)

In 1930 there was observed by Dam and his assistants that new-born chicken, when provided with fodder free from lipoid, suffered from cutaneous and mucosal haemorrhages, and it was found that such haemorrhages were caused by the lack of a vitamin occurring in green vegetable parts and unknown up to that time. This vitamin was called "anti-haemorrhagic vitamin" or "vitamin K". Later on Karrer and Doisy managed to educe the vitamin K<sub>1</sub> in pure condition and to determine it, upon further experiments, as a derivate of 1·4-naphthochinon.

To-day two natural K-vitamines are distinguished:

K<sub>1</sub>, is of vegetable origine

(contained in spinach, cabbage, lucerne, tomato, Alfalfa-hay),

K<sub>2</sub>, is of animal origine

(isolated from rotting fish-flour).

Both are fat-soluble and resorbable only in presence of gallic acids. Whereas the vitamin K<sub>2</sub> has only an efficiency of about 60 % of that of vitamin K<sub>1</sub>, a simple derivaste of the 1·4-naphthochinon, i.e. the

2-methyl-1·4-naphthochinon

in respect to its therapeutical effect essentially surpassed the vitamin K<sub>1</sub>.

#### Properties:

The 2-methyl-1·4-naphthochinon-sodium bisulphite

#### VITAMIN K "PHARMA"

produced in our works is an especially high-valued therapeutical product of water-soluble condition which, in contradistinction to natural vitamines K<sub>1</sub> and K<sub>2</sub>, is resorbed by the intestine even in absence of bile, and does not entail any intoxication even in the event of considerable overdosing.

Whereas the therapy was interested up to now substantially in the antihaemorrhagic effect of the vitamin K nowadays also two recently discovered and still nearly unknown properties of the vitamin K are gaining considerable importance, and that its antibacterial and anticarious efficiency.

#### Effect:

In case of lack of vitamin K the clotting power of the

- 3 -

blood is prolonged with the leaching level of prothrombin. The clotting process may be outlined as follows:

1. Activation of the ferment prothrombin by vitamin K which is necessary for the formation of prothrombin.
2. Conversion of the activated prothrombin, in presence of Calcium and the ferment thrombokinase, into thrombin.
3. Formation of fibrin, under the effect of thrombin, from the colloidally dissolved albuminous body present in the plasma.

The lack of vitamin K may be caused

1. by disturbed formation of prothrombin, due to damages the liver-cells are afflicted with,
2. by physiological hypoprothrombinemia of new-born babies during their first week of age, due to a still insufficient function of the liver resulting from a probably present impermeability of the placenta for vitamin K as well as from the absent bacterial flora of the intestine which is the main source of vitamin K,
3. by restricted resorption of fats and, in this way, also of the fat-soluble vitamin K, due to blocked bile-ducts as resulting e.g. from gallstones and tumours.

As to the anticarious and antibacterial properties

U.S. Fosdick and other authors found in course of their work:

1. In saliva and the mouth respectively sugar is easily converted into acid products decalcifying the teeth and favouring the occurrence of caries.
2. Vitamin K, according to Fosdick a ferment suppressing matter, prevents the saliva to decompose sugar into acid products, thus excluding their injurious effect on the teeth and taking care of a prophylactic anticarious efficiency.

The caries, moreover, can be influenced by vitamin K from the buccal part, too.

3. Vitamin K inhibits in and even outside the mouth the formation of certain bacteria and fungi.

#### Indications:

In case of lack of vitamin K the indications result from the given causes whereas Coethgens's examinations of new-born babies in respect to the morbus haemorrhagicus neonatorum and physiologic jaundice of the newborn child are of special

- 4 -

of the liver is substantially strengthened if a vitamin K 25X1 refractory reduction of the level of prothrombin is found. In the event of the vitamin K refractory hypoprothrombinemia lessening below 30 % the suspicion of an acute dystrophy of the liver, at further reduction that of a coma hepaticum would be given.

The following procedure should be adhered to: discharge of 5, resp. 10 ccm oxalic blood in the morning in jejune condition (i.e. 1 ccm of 1.34 % sodium oxalate and 9 ccm of blood), quantitative determination of the prothrombin according to Quick. Subsequently to the discharge of blood intramuscular injection of 30 mgs of vitamin K, after 24 hours repeated determination of the level of prothrombin.

#### Dosage:

The therapeutic dosage ranges normally between 10 and 20 milligrams per day, and that for 1 to 3 days once or twice a day one ampoule injected intramuscularly, intravenously or subcutaneously, or for 8 days thrice a day 1 to 2 sugared pills or evtl. combined parenteral and oral application. In acute cases the dosage may be increased up to 50 to 100 milligrams (to be applied by slow, intravenous injections) since light injuries of animals have not been observed unless upon doses which are never applied in clinical practice (e.g. 10 milligrams per kilogram body-weight resulting in light vomiting of dogs).

#### Packings for Sale:

Boxes of 5 ampoules of 1 ml each = 10 milligrams  
 Boxes of 25 ampoules of 1 ml = 10 milligrams each  
 Boxes of 5 ampoules of 2 ml each = 100 milligrams  
 Tubes of 20 sugared pills of 10 milligrams each  
 Glass of 250 sugared pills of 10 milligrams each.

#### Literature:

1. Tanner and Suter, Schweiz.Med.schr. 74, 552 (1943)
2. Koller, F. and A. Pedrazzini, Schweiz.Med.schr. 911 (1947)
3. Kreitmair, Med.Klinik 23/561-66 (1946)
4. Ludwig von Vargo, Arztl.Forschung 151/57 (1948)
5. Lam, Nature (London) 133-139 (1934)
6. Dem, Zeitschrift für Vitaminforschung 9-71 (1939)
7. Geethgens, "Das Vitamin K in der Physiologie und Pathologie der Frau und der Neugeborenen", G.v.Thieme Verlag, Leipzig, (1946)

- 6 -

8. Geethgens, Arztl.Forschung 255/264 (1948)
9. Koller, "Das Vitamin K und seine klinische Bedeutung", Gg. Thieme Verlag, Leipzig (1941)
10. Schüler, Arztliche Tschr. 55-56 (1948)
11. R.R. Gordon, The Lancet 6556 : 692 (1949)
12. Dr. A.Bénos, Arch.Kinderkh. 133 (1946)
13. Cvilichovskaja, M.E.Suvalova, N.N.Chelabusarj, A.M. Timofejews, Klin.Medizin 4-5/XIV, 59-65 (1946)
14. F. Hauser, Annales Paediatrici, Vol.168, No.1 (1947)
15. A.Hermann Müller, Z.f.d.ges.Inn.Med. 9/10 S, 284/88 (1947)
16. P. Kallos, Gastroenterologica 3 (1946)
17. E. Uhse, "Das Vitamin K in der Behandlung des Keuchhustens" Das Deutsche Gesundheitswesen No.19 (1953)
18. "Die Vitamine" (Schweiz) No.3 (1952): "Zwei noch wenig bekannte Eigenschaften des Vitamin K"
19. E. Uhse: "Das Vitamin K in der Behandlung des Keuchhustens. Neue Erkenntnisse der Vitamin K - Wirkungen." Das Deutsche Gesundheitswesen No.37 (1954)

Export Informations may be obtained from:

Deutscher Innen- und Außenhandel Chemie,  
Berlin C 2, Schicklerstraße 5-7

Olypon AFE

as auxiliary colouring matter for sulphur dyeing (Textiles)

25X1

Introduction

The Sulphur dyes being mostly insoluble in water are for dyeing purposes made soluble by reducing them. The reduction of the dye stuff is carried out by means of sulphuret of sodium which simultaneously serves as a solvent for the reduced dye stuff. The required quantity of soda increases the alkalinity in order to prevent any decomposition of the sulphuret of sodium. The application of the dissolved dye stuff to the fibre is improved by the addition of Glauber's salt. The required quantities of sulphuret of sodium, soda, and Glauber's salt should be taken from the instructions issued by the dye factories.

Dissolution of the Sulphur Dye:

The dye stuff is made doughy in hot water by adding the appropriate quantity of sulphuret of sodium, and subsequently boiled up. For improving the doughing and dissolving of the dye stuff Olypon AFE (see fig.2) is added. For one litre normally 0.5 to 1 gram of Olypon AFE are used.

Properties of the Olypon AFE (D.P. ....)

Olypon AFE is sold in shape of a brown, water-soluble oil. In chemical respect it is a condensate of fatty acid. Owing to its excellent qualities it is one of the best textile auxiliaries of modern times. Beside its extraordinary resistivity against hardeners it owns a good capability of cleaning, soaking, dispersing, and foaming, and it is suitable to any neutral, alkaline, and acid colour dyes. Olypon AFE may be mixed up with water in any ratio, and it is perfectly fast to boiling, even when boiled under pressure.

10 ccm NaOH 26° Be  
in 1 ltr H<sub>2</sub>O 15° DH

10 ccm NaOH 26° Be  
2 gs of Olypon AFE  
in 1 ltr. H<sub>2</sub>O 15° DH  
no precipitation

Precipitation

Figure No. 1



The dissolution

25X1

The naphthols can be dissolved according to two procedures, and that:

- 1) by hot dissolution, and
- 2) by cold dissolution.

's to 1): The naphthol is well doughed with Olypon A/F, then the corresponding dose of soda lye of 38°Bé is added, and subsequently hot water is added in exact adherence to the prescription. When doing so take care of obtaining a clear solution. Otherwise we recommend to boil up shortly the solution. According to the prescriptions now the required quantities of cold water are added as well as 33 per cent formaldehyde, and then the required volume is filled up.

's to 2): The naphthol is dissolved according to prescription paying attention only to the Olypon A/F being added to the grounding bath. 1 to 2 grams of Olypon A/F per litre will suffice.

filter test

10 g naphthol AS	20 g Naphthol AS
- Olypon A/F	3 g Olypon A/F
15 ccm NaOH 38°Bé	15 ccm NaOH 26°Bé
150 ccm H <sub>2</sub> O hot	150 ccm H <sub>2</sub> O hot
150 ccm H <sub>2</sub> O cold	150 ccm H <sub>2</sub> O cold
10 ccm formaline	10 ccm formaline
1000 ccm to be filled up	1000 ccm to be filled up
<u>developed with:</u>	<u>developed with:</u>
50 ccm Echtrot-salt TR (1:100)	50 ccm Echtrot-salt TR (1:100)

Figure No.3

without Olypon A/Fwith Olypon A/FGeneral:

It is of special importance for naphthol dyeing to keep the baths of the dissolved naphthol in solution as long as possible, and that both in diluted and in concentrated brine (see fig.4). It is very important, furthermore, to add to the grounding bath a first-class soaking agent so as to attain a good grounding effect.

Both requirements for naphthol dyeing are complied with by Olypon AFE.

Olypon AFE is a high-valued protective colloid of high soaking effect. Even in hard water the naphthol solutions remain clear. Attention should be paid only to the Olypon AFE (1 g/ltr<sup>o</sup>) being added to the grounding bath before any other additions are added.

10 gs naphthol AS  
21 ccm NaOH 26 Be  
150 ccm hot H<sub>2</sub>O  
150 ccm cold H<sub>2</sub>O  
10 ccm formaline

filled up to:

1000 ccm H<sub>2</sub>O 15 DH

after short time no precipitation

10 gs naphthol AS  
10 ccm Olypon AFE (30:70)  
21 ccm NaOH 26 Be  
150 ccm hot H<sub>2</sub>O  
150 ccm cold H<sub>2</sub>O  
10 ccm formaline

filled up to:

1000 ccm H<sub>2</sub>O 15 DH  
+ 1 ccm Olypon AFE

(30:70)  
+ 6 ccm NaOH 26 Be

the naphtholate solution remains clear.

Figure No.4

#### Indanthrene Dyeing

As everybody knows indanthrene dye stuffs cannot be dyed unless at 60° C. Practical experiences have shown difficulties in the dyeing of perlon materials with indanthrene dye stuffs: for obtaining a certain shade it is necessary to increase the temperature up to 90° C.

It is not unknown that the bath tends to break down at higher temperatures. For maintaining the bath considerable quantities of hydrosulfite are required. Upon addition of Olypon AFE the bath remains unchanged in spite of the increased temperature, and that without addition of larger quantities of hydrosulfite. In other words: by the addition of Olypon AFE we are in a position to dye also indanthrenes at 90° C without extra consumption of hydrosulfite.

Without prejudice!

VEB Chemische Fabrik Grünau  
Berlin-Grünau  
Regattastrasse 35  
Tel. 644061

Composition of the Preparations Listed in the  
Veterinary Drug Catalogue 1956

25X1

Arsenic Cures for Horses

	20 %	30 %	50 %
Arsenious acid	20 %	30 %	50 %
Filling agent to 100 %			

Ointment B.T.Z

Ointment base	85.0 %
Benzoic acid	
Turpentine-oil	
Glycerine	
Oxide of zinc	

The biocatalysts are composed according to special prescription.

Powder for Glanders

Gentian-root	
Fennel-seed	
Juniper-berries	
Fenugreck seed	
Glauber's salts	
Chloride of soda	
Stibium sulphuratum nigrum	

The composition is made according to special prescription.

Ointment for Inflammatory Swellings

Ointment base	80.0 %
Gray quicksilver salve	
Camphor	
Cade-oil	

The biocatalysts are composed according to special prescription.

Embocation

Emulsion base                    88.0 %  
 Camphor  
 Turpentine-oil  
 Oil of mustard                    10.0 %  
 Solution of ammonia

The biocatalysts are composed according to special prescription.

Udder Ointment E

Ointment base                    78.0 %  
 Aluminium acetate  
 Turpentine-oil

The biocatalysts are composed according to special prescription.

Falkitol-pills for Horned Cattle and Sheep

The biocatalysts are composed according to special prescription, and that on base of hexa-ethyl-chloride.

Tetter Ointment

Ointment base                    87.0 %  
 Solution of formaldehyde  
 Camphor

Lubricant

Celline  
 Sterilizer

The components are dosed according to special prescription.

Hippascan                        Benzene oil, oil of camphor, oil of turpentine, oil of lavender.  
 Arsenious acid  
 Carbonate of potash  
 Sterilizer  
 Solvent

The components are dosed according to special prescription.

Cod-liver Ointment

25X1

Ointment base 80.0 %  
Cod-liver-oil

Cod-liver Zincointment

Ointment base 63.0 %  
Cod-liver-oil  
Oxide of zinc  
Sterilizer

The biocatalysts are composed according to special prescription.

Milking-grease

Vaseline  
Glycerine  
Sterilizer

The components are dosed according to special prescription.

Ear-oil for Small Cattle

Hexantriol  
Balsam Peru

The components are dosed according to special prescription.

Panaritan

Sulphate of zinc  
Sulphate of copper  
Alum  
Tannic acid  
Coal-preparations for absorption

The components are dosed according to special prescription.

Susacen

Arsenious acid	25X1
Carbonate of potash	
Sterilizer	
Solvent	85.0 %

The biocatalysts are composed according to special prescription.

---

Sulphonamide Dusting Powder 10%, 20%

Powder base	90.0 %
p-aminophenylsulphonamide	

---

Tannoform Dusting Powder

Powder base	80.0 %
Tannoform	

---

Tannosal

Powder base	66.0 %
Oak-bark	
Tannic acid	
Salicylic acid	
AEB (X) Chemische Fabrik Bitterfeld	
Tannalbin	
SS-55	
<del>Bestekneese per fedberg, Delft power plant</del>	

The biocatalysts are composed according to special prescription.

---

Tinct. Stomachica Amara

Tincture of worm-wood  
Tincture of gentian  
Tincture of scorus.

The components are dosed according to special prescription.

---

Camphor Ointment 10%, 20%

Ointment base	90.0 %
Camphor	

---

- 4 -

Emulsion "PL"

Emulsion base  
Glycerine  
Perugene

glycerin  
85.0%  
glycerin  
glycerin

The biocatalysts are composed according to special prescription.

-----Composition is provided2% Pyoctanine Solution

Pyoctanine 3%

Solvent

glycerin  
glycerin  
glycerin  
glycerin

100% of pyoctanine dissolved in glycerin acid  
and citric acid

Rivanol Ointment for the Eyes with Pantocain

Eye-ointment base  
Rivanol  
Pantocain

99.5%  
glycerin

glycerin  
glycerin

The biocatalysts are composed according to special prescription.

100% of rivanol dissolved in glycerin acid

Rivanol Dusting Powder

Powder base  
Rivanol

95.0%

glycerin  
glycerin

100% of rivanol dissolved in glycerin acid

Rumivet Simple

Tincture of worm-wood  
Tincture of hellebore  
Tincture of scorus  
Hydrochloric acid

glycerin

glycerin  
glycerin

The components are dosed according to special prescription.

100% of rumivet dissolved in glycerin acid

Rumivet Forte

Chlorate of barium  
Tincture of hellebore  
Hydrochloric acid

The components are dosed according to special prescription.

- 5 -

Suasean

25X1

Arsenious acid	
Carbonate of potash	
Sterilizer	
Solvent	85.0 %

The biocatalysts are composed according to special prescription.

Sulphaphenamide Dusting Powder 10% 20%

Powder base	90.0 %
p-aminophenylsulphonamide	

Tannoform Dusting Powder

Powder base	80.0 %
Tannoform	

Tannosal

Powder base	66.0 %
-------------	--------

Oak-bark

Tannic acid

Salicylic acid

~~Camphor~~

Tannabine

SS-81 ~~Chemische Fabrik List~~ ~~Stiftung für chemische Produkte~~

The biocatalysts are composed according to special prescription.

Tinct. Stomachica Amara

Tincture of wormwood

Tincture of gentian

Tincture of scoros

The components are dosed according to special prescription.

Camphor Ointment 10% 20%

Ointment base	90.0 %
Camphor	

- 5 -

- 6 -

Camphor Ointment and Ichthyol Ointment

Ointment base	90.0 %
Ichthyols	
Camphors	

Ichthyol Ointment 10% 20% 50%

Ointment base	90.0 %
Ichthyols	

Ointment of Salicylic Soap with Camphor and Iodine

Ointment base	50.0 %
Salicylic acid	
Methylum salicylicum	
Camphor	
Iodine	

The biocatalysts are composed according to special prescription.

VEB (K) Chemische Fabrik Falkensee,  
Falkensee bei Berlin, Dallgower Straße 16-22  
(Betriebsnummer: 04/4462)

Deutscher Text  
Seite:

- 1 -

Umschlag I CFF - VEB (K) Chemische Fabrik Falkensee

25X1

Falkensee bei Berlin, Dallgower Str. 16-22

Phone:

Falkensee 3027

Catalogue of Veterinary Drugs

January, 1956

**Umschlag II** By this catalogue we beg to give you a summary on our veterinary drugs produced at present time (January 1, 1956). -

The veterinary drugs produced in our works are sold to veterinarians and drugstores only. In special cases, however, and upon veterinary prescription direct supplies to final users are possible.

- 1 - (- Siehe Umschlagseite I ! -)

<u>Description</u>	<u>Indication</u>	<u>Packing</u>
<u>Arsenic Cures for Horses</u>		35 packed powder doses of 1 g each, for one treatment of 5 weeks
<u>B.I.Z.-Ointment A</u>	For the treatment of wounds as well as itching and antiphlo- gistic skin-diseases, eczema and other cutaneous damages	Porcelain box of 100 grams
<u>Powder for Horse</u>	For diseases of the larger air-passages as well as for strangles	Packing of 250 gs
<u>Ointment for In- flammatory Swellings</u>	Resolvent	Box of 100 grams
<u>Embrocation A</u>	Antiphlogistic, anti- neuralgic for absorbing massages irritating the skin in case of rheumatic diseases of any kind, arthritis, phlegmons, etc.	Glass bottles of 200 ml each

- 2 -

25X1

Deutscher Text  
Seite:

- 2 -

25X1

- 3 -

<u>Designation</u>	<u>Indication</u>	<u>Packing</u>
<u>Udder Ointment E</u>	For phlegmons and per- enanthematous inflammations of the udder, for epithelial diseases as well as inflammatory eczema	Porcelain bottle of 100 grams
<u>Felkitol-pills A</u>	For combating against the fluke-worm disease of horned cattle and sheep	for horned cattle: (10g) box of 40 pcs for sheep: (8 g) box of 14 pcs
<u>Tetter Ointment</u>		Box of 100 grams
<u>Lubricant</u>	Non-greasing arm lubricant, disinfecting, washable. For rectal and vaginal obstetrics, suitable to being used as substitute of amniotic liquor	Bottle of 1000 ml, balloon of 25 kgs
<u>Hippasean A Rp</u>	Reliable worm lubricant for escarides of horses and foals, also acting against strongylides	Bottles of 200 ml each
<u>Cod-liver Ointment A</u>	As vulnerary and curing ointment especially indicated for bad-healing ulcers, fistulas and burns as well as for the treatment of eczema	Porcelain box of 100 grams
<u>Cod-liver Zinc-ointment A</u>	For erosions, wounds, penaritis, and as lubricant and protective ointment for obstetrics and for rectal examinations	Porcelain box of 100 grams
<u>Milking-grease</u>	For softening and dis-infecting the milker's hands and the teats	Boxes of 500 and 1000 grams

- 3 -

Deutscher Text  
Seite:

- 3 -

- 4 -  
(Forts.)

	Designation	Indication	Packing
	<u>Ear-oil for small Cattle</u>	For otitis externa ceruminosa, especially otitis externa parasitaria of dogs, cats, and rabbits	Bottles of 30 ml each
	<u>Panaritan A Rp</u>	Desiccative, leniently cauterizing dusting powder for panaritia, wart malanders, malanders, laming due to mustiness as well as for after-treatment of cancer of the hooves	Parcel of 100 gs
- 5 -	<u>PL-emulsion A</u>	For promoting the granulation and epithilization process, for use as hair-restorer in alopecia as well as for heavily iching skin-diseases, particularly with small cattle practice	Bottle of 100 ml
	<u>Pix Liquida</u>	Antiseptic	Balloon box of 1 kg
	<u>Pyocyanin Solution</u>	Sterilizing agent for chafed wounds	Bottle of 100 ml
	<u>Rivanol-Dusting Powder</u>	Antiseptic powder	Dusting box of 50 grams
	<u>Rumivet A Rp</u>	For acute and chronic gastric and intestinal catarrhs, stimulating contraction and peristalsis, promoting ruminating	Glass bottle of 100 millilitres
	<u>Rivanol Ointment for the Eyes with Pantocain A Rp</u>	Alleviating and anti-itching ointment for the eyes in conjunctivitis, keratitis, blepharitis	Porcelain box of 10 grams

- 4 -

25X1

Deutscher Text

Seite:

- 4 -

- 6 -

	<u>Designation</u>	<u>Indication</u>	<u>Packing</u>
	Rumivet Forte A Rp	Strong Rummation promoting agent similar to Rumivet	Bottle of 100 ml
141.	Suascan A Rp	Vermicide for pigs and young pigs affected by ascarides, also used for resolving arsenic cures for swines, sheep, and she-goats	Bottle of 100 ml
	Sulphonamide Dust- ing Powder 10, 20, and 50 % A Rp	For poisoned wounds, malign oedema, gas-gangrene, burns, frost-bites, otitis, cancer of hooves, etc.	Dusting box of 100 grams
	Tannoform Dusting Powder A	For wounds of most different kind as well as drying antiseptic for wet malanders	Dusting box of 100 grams
	Tannosal A	Astringent medicine and intestinal disinfective especially for diarrhoea, dysentery of calves, tympany	O.P. 100 grams
- 7 -	Tinct. Stomachica Amora A	For anorexia of beasts of any kind, also as roborentien tonic in debility, dyspepsia, etc.	Bottle of 100
	Camphor Ointment 10 and 20 % A	For provoking local hyperaemia in case of phlegmons, inflammations of udder and lymphatic glands, suppurative tendovaginitis, bed-granulating wounds, ulcers, and fistulae	Box of 100 grams

- 5 -

Deutscher Text

Seite:

- 7 -  
(Forts.)

Designation	Indication	Packing
Ungt. Camph. et Ungt.	Antiseptic for	Porcelain bottle
Ichthyoli 1:1 A	wounds and hurts	of 100 grams
Ungt. Ichthyol 110, 20, and 50 % A	Antiseptic agent for wounds and hurts	Porcelain bottle of 100 grams
Ungt. Sepo Salic. cum Camph. et Iod. A	Laming, Rheuma	Porcelain bottle of 100 grams
White Oil Pharm.		Bottles of 1 kg, and large parcels

- 8 -

CONDITIONS FOR SALE AND DELIVERY

## Offers:

Our offers are not obligatory. Mutual, contracted obligations are not binding unless upon our confirmation of order in writing.

## Delivery:

The buyer bears any risk of transportation, even in the event of agreed free delivery. In case of force majeure we are entitled to postpone the delivery for the time of such condition or to withdraw from the contract in total or partially. Claims are considered only when notified within 8 days following the receipt of the goods.

## Sent Packings:

The sent packings should be carefully treated and returned, in accordance to Official Gazette No.125 dated 28/11/1953,

- a) from large industrial works within 45 days,
- b) from any other enterprise within 30 days.

## Property Reserved:

Supplied goods incl. packing remain in our property until complete payment is effected.

## Payment:

Terms of payment in accordance to the 6<sup>th</sup> ordonnance to the Enactment Concerning the Financial Economy of people's-own Enterprises. The invoiced amount should be paid not later than 15 days from the date of the invoice, and without any reduction. In the event of delayed payment, the buyer has to pay for interests on account of deferred payment which amount to 8 %

Deutscher Text

- 6 -

Seite:

- 8 - p.s. of the invoiced sum.

(Porte.)

**Settling Place and Competence of Court:**

The settling place is our factory store in Falkensee.

The competent court is that which is competent for Nauen.

**VEB (K) CHEMISCHE FABRIK FALKENSEE**

**Umschlag III Out of our manufacturing program we recommend to use  
the highly effective fine-disinfectant**

**B A C T O S E P T**

**Z**

**CONTAINING THE BIOCATALYST Z 2**

**bactericide fungicide**

**CFF**

• 1000 ml. = 1 liter

• 100 ml. = 100 ml.

• 10 ml. = 10 ml.

• 1 ml. = 1 ml.


• 100 g. = 100 g.

• 10 g. = 10 g.

• 1 g. = 1 g.

• 10 mg. = 10 mg.

• 1 mg. = 1 mg.



25X1

Sanitized Copy Approved for Release 2010/02/16 : CIA-RDP80T00246A032301010001-0

**Page Denied**

25X1

Sanitized Copy Approved for Release 2010/02/16 : CIA-RDP80T00246A032301010001-0